What is the role of pharmacogenetics in clinical psychiatry?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 1-4

  Lombard, Jay ^a,b   Doraiswamy, P Murali ^c  

^a Genomind LLC   (United States)

^b Touro University College of Pharmacy and School of Osteopathic Medicine   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Drug metabolism; Efficacy; Pharmacogenetics; Pharmacogenomics; Psychiatry

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BIOLOGICAL MARKER; CITALOPRAM; ESCITALOPRAM; HYPNOTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DRUG METABOLISM; HUMAN; PHARMACOGENETICS; PROGNOSIS; PSYCHIATRY; REVIEW; SOCIAL PSYCHOLOGY;

GENETIC MARKERS; HUMANS; MENTAL DISORDERS; PHARMACOGENETICS; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 84871215814     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.733696     Document Type: Review

References (20)

1. National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying. Table 95 Hyattsville, MD: 2011
2. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. N Engl J Med 2005;353(12):1209-23
3. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARI report. Am J Psychiatry 163(11):1905-17
4. Zhang J, Malhotra A. Pharmacogenetics and Antipsychotics: therapeutic Efficacy and Side Effects Prediction. Expert Opin Drug Metab Toxicol 2011;7(1):9-37
5. Brunton L, Lazo J, Parker K. Goodman and Gilman's the pharmacological basis of therapeutics. 11th edition. McGraw Hill; New York: 2006
6. Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci 2010;12(1):69-76
7. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet 2009;48(11):689-723
8. de Leon J, Susce MT, Murray-Carmichael E. The AmpliChipCYP450 genotyping test: Integrating a new clinical tool. Mol Diagn Ther 101 3 135-135
9. Patroneva A, Connolly SM, Fatato P. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. Drug Metab Dispos 2008;36(12):2484-91
10. Hendset M, Molden E, Refsum H, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 2009;29(6):537-41
11. Tsai MH, Lin KM, Hsiao MC, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010;11(4):537-46
12. Feng Y, Pollock BG, Coley K, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008;66(5):629-39
13. de Leon J, Armstrong SC, Cozza KL. The dosing of atypical antipsychotics. Psychosomatics 2005;46(3):262-73 (Pubitemid 40594318)
14. Caspi A, Hariri AR, Holmes A, et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. J Psychiatry 2010;167(5):509-27
15. Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5- HTTLPR) association with
16. antidepressant efficacy. Eur Neuropsychopharmacol 2012;22(4):239-58
17. Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15(5):473-500
18. MacMohan FJ, Insel TR. Pharmacogenetics and personalized medicine in neuropsychiatry. Neuron 2012;74(5):773-6
19. Malhotra AK, Zhang JP, Lenz T. Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 2012;17(8):760-9
20. Hulse GK. Improving Clinical Outcomes for Naltrexone as a Management of Problem Alcohol Use. Br J Pharmacology 2012; [Epub ahead of print] www. fda.org Available from: www.fda.org